New hope for Hard-to-Treat ovarian cancer? early trial tests drug combo

NCT ID NCT05276973

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing the safety and best dose of a new drug called ipatasertib when given alongside standard chemotherapy drugs (paclitaxel and carboplatin) to patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if adding ipatasertib, which blocks enzymes cancer cells need to grow, makes the standard treatment more effective at controlling the cancer before surgery. The study involves about 25 participants who have not had prior treatment for their cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Augusta University Medical Center

Augusta, Georgia, 30912, United States
Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
UCSF Medical Center-Mission Bay

San Francisco, California, 94158, United States
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
Virginia Commonwealth University/Massey Cancer Center

Richmond, Virginia, 23298, United States
Women and Infants Hospital

Providence, Rhode Island, 02905, United States

Conditions

Explore the condition pages connected to this study.

FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA OVARIAN ENDOMETRIOID ADENOCARCINOMA OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA STAGE III FALLOPIAN TUBE CANCER AJCC V8 STAGE III OVARIAN CANCER AJCC V8 STAGE III PRIMARY PERITONEAL CANCER AJCC V8 STAGE IV FALLOPIAN TUBE CANCER AJCC V8 STAGE IV OVARIAN CANCER AJCC V8 STAGE IV PRIMARY PERITONEAL CANCER AJCC V8 UNRESECTABLE FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA UNRESECTABLE FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA UNRESECTABLE OVARIAN ENDOMETRIOID ADENOCARCINOMA UNRESECTABLE OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA UNRESECTABLE PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA UNRESECTABLE PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA